Patent intelligence · US
US 11744873
Compositions and methods for the treatment of metabolic and liver disorders
Compositions and methods for the treatment of metabolic and liver disorders
Patent details — US 11744873
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 5, 2023
- Expiration
- Aug 31, 2043
- Applicant
- Viking Therapeutics, Inc.
- Claims
- 25
- CPC classes
- A61K, A61K38/16, A61K47/542, A61P
Quick answer
US 11744873 (Compositions and methods for the treatment of metabolic and liver disorders) is held by Viking Therapeutics, Inc.. Status: granted. Granted Sep 5, 2023. Expires Aug 31, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Viking Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K38/16, A61K47/542, A61P, A61P1/16, A61P43/00
More from Viking Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421282
Compositions and methods for the treatment of metabolic and liver disorders
granted -
US 12318426
Compositions and methods for the treatment of metabolic and liver disorders
granted -
US 12102646
Compositions for the treatment of fibrosis and inflammation
granted -
US 12083184
Hydrogel prodrug for treatment
granted -
US 11951114
Use of thyroid beta-agonists
granted -
US 11752217
Hydrogel prodrug for treatment
granted -
US 11707472
Compositions for the treatment of fibrosis
granted
Frequently asked questions
What is US patent 11744873?
US 11744873 (Compositions and methods for the treatment of metabolic and liver disorders) is held by Viking Therapeutics, Inc.. Status: granted. Granted Sep 5, 2023. Expires Aug 31, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11744873?
Viking Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 15 pharmaceutical patents for this assignee.
When does US 11744873 expire?
Our index shows an expiration date of Aug 31, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.